What is Zacks Research’s Forecast for CORT Q1 Earnings?

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Zacks Research lifted their Q1 2025 EPS estimates for Corcept Therapeutics in a research note issued to investors on Wednesday, January 29th. Zacks Research analyst K. Das now forecasts that the biotechnology company will post earnings per share of $0.29 for the quarter, up from their prior forecast of $0.27. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q1 2026 earnings at $0.48 EPS, Q3 2026 earnings at $0.75 EPS and FY2026 earnings at $2.53 EPS.

A number of other research firms have also recently weighed in on CORT. StockNews.com cut Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 25th. Sandler O’Neill reaffirmed a “buy” rating on shares of Corcept Therapeutics in a report on Friday, October 18th. Canaccord Genuity Group upped their target price on Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Corcept Therapeutics in a research report on Thursday, October 31st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $88.25.

Corcept Therapeutics Stock Up 13.6 %

CORT stock opened at $69.90 on Friday. Corcept Therapeutics has a fifty-two week low of $20.84 and a fifty-two week high of $70.60. The company’s 50 day moving average price is $55.83 and its 200 day moving average price is $46.67. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70. The firm has a market capitalization of $7.32 billion, a price-to-earnings ratio of 55.48 and a beta of 0.56.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.27 by $0.14. The business had revenue of $182.55 million during the quarter, compared to the consensus estimate of $171.97 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The company’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.28 earnings per share.

Institutional Trading of Corcept Therapeutics

A number of institutional investors have recently modified their holdings of the company. Capital Performance Advisors LLP purchased a new stake in Corcept Therapeutics during the third quarter worth approximately $25,000. Kathleen S. Wright Associates Inc. purchased a new stake in shares of Corcept Therapeutics in the third quarter worth about $36,000. USA Financial Formulas purchased a new stake in shares of Corcept Therapeutics during the 4th quarter valued at about $54,000. Newbridge Financial Services Group Inc. acquired a new position in Corcept Therapeutics during the 4th quarter worth approximately $58,000. Finally, Principal Securities Inc. raised its stake in shares of Corcept Therapeutics by 63.6% during the fourth quarter. Principal Securities Inc. now owns 1,243 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 483 shares during the period. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Insider Transactions at Corcept Therapeutics

In other news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $50.54, for a total transaction of $111,188.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Joseph Douglas Lyon sold 1,411 shares of the stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $56.72, for a total transaction of $80,031.92. Following the transaction, the insider now directly owns 8,494 shares in the company, valued at approximately $481,779.68. This represents a 14.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 31,405 shares of company stock valued at $1,627,772 in the last 90 days. 20.50% of the stock is currently owned by insiders.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.